
Full text loading...
Category: Immunology
Monitoring of Immunologic Therapies, Page 1 of 2
< Previous page | Next page > /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH110-1.gif /docserver/preview/fulltext/10.1128/9781555818722/9781555818715_CH110-2.gifAbstract:
Immunologic therapies are becoming increasingly widely utilized. The current interest in these therapies is due to considerable successes in treatment outcomes in a broad spectrum of human diseases targeted for biotherapy, including inheritable or acquired immunodeficiencies, autoimmune diseases, cancer, and persistent infections. Many new biologic agents are available for immune therapy, and antibodies, cytokines, activated or genetically modified immune cells, vaccines, and other immunomodulatory drugs are frequently used either as monotherapies or in combination with conventional therapies such as chemotherapy, radiation, surgery, and even behavior-modifying therapies. In cancer, biotherapies are expected to restore dysfunctional antitumor immune responses, activate immune cells, and help immune cells to reacquire normal homeostasis. In addition, tumors resistant to standard therapies are often sensitive to immune interventions, and this offers a promise of combinatorial therapies to overcome drug resistance.
Full text loading...
Immunologic assays currently available for monitoring of phase I/II clinical trials with biologic agents
Immunologic assays currently available for monitoring of phase I/II clinical trials with biologic agents